Atyr Pharma Inc (NASDAQ: ATYR) kicked off on Monday, down -16.56% from the previous trading day, before settling in for the closing price of $3.95. Over the past 52 weeks, ATYR has traded in a range of $1.42-$4.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 545.22%. While this was happening, its average annual earnings per share was recorded 3.09%. With a float of $81.24 million, this company’s outstanding shares have now reached $83.94 million.
Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is -563.83%, operating margin of -28958.72%, and the pretax margin is -27155.32%.
Atyr Pharma Inc (ATYR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Atyr Pharma Inc is 3.22%, while institutional ownership is 65.86%. The most recent insider transaction that took place on Feb 04 ’25, was worth 4,740. In this transaction Chief Financial Officer of this company sold 1,254 shares at a rate of $3.78, taking the stock ownership to the 31,763 shares. Before that another transaction happened on Feb 04 ’25, when Company’s General Counsel sold 899 for $3.78, making the entire transaction worth $3,398. This insider now owns 26,555 shares in total.
Atyr Pharma Inc (ATYR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.29% during the next five years compared to 43.36% growth over the previous five years of trading.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Take a look at Atyr Pharma Inc’s (ATYR) current performance indicators. Last quarter, stock had a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1204.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Looking closely at Atyr Pharma Inc (NASDAQ: ATYR), its last 5-days average volume was 1.89 million, which is a jump from its year-to-date volume of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 25.90%. Additionally, its Average True Range was 0.33.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 51.94%, which indicates a significant increase from 0.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 117.94% in the past 14 days, which was higher than the 83.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.67, while its 200-day Moving Average is $2.58. However, in the short run, Atyr Pharma Inc’s stock first resistance to watch stands at $3.78. Second resistance stands at $4.25. The third major resistance level sits at $4.50. If the price goes on to break the first support level at $3.06, it is likely to go to the next support level at $2.81. Now, if the price goes above the second support level, the third support stands at $2.34.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
The company with the Market Capitalisation of 277.01 million has total of 83,942K Shares Outstanding. Its annual sales at the moment are 350 K in contrast with the sum of -50,390 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -16,310 K.
